Lung Cancer:@0.792682:0.035749:0.914564:0.035749:0.914564:0.019993:0.792682:0.019993:0.008890:0.011699:0.011738:0.012950:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
37:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
or  adding additional cycles of chemo- :@0.084242:0.096166:0.480482:0.096166:0.480482:0.080410:0.084242:0.080410:0.012604:0.005792:0.005330:0.006261:0.013143:0.013181:0.013181:0.003848:0.011738:0.012950:0.011603:0.013143:0.013181:0.013181:0.003848:0.006523:0.003848:0.012604:0.011738:0.013143:0.003848:0.011603:0.012450:0.010314:0.012450:0.003848:0.012508:0.007466:0.011603:0.012604:0.006042:0.011603:0.012450:0.011738:0.012508:0.018049:0.012604:0.006381:0.005330
therapy.:@0.084242:0.112557:0.162713:0.112557:0.162713:0.096801:0.084242:0.096801:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
The overall response rate in patients with :@0.102426:0.128947:0.480507:0.128947:0.480507:0.113192:0.102426:0.113192:0.008197:0.011738:0.012508:0.004699:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.004714:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.004714:0.005792:0.013143:0.006523:0.012508:0.004701:0.003848:0.011738:0.004714:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004714:0.015990:0.003848:0.006523:0.011738:0.005330
LD and ED is approximately 75% and 50%, :@0.084242:0.145338:0.480505:0.145338:0.480505:0.129582:0.084242:0.129582:0.008890:0.014316:0.006090:0.013143:0.011738:0.013181:0.006100:0.010314:0.014316:0.006090:0.003848:0.007466:0.006100:0.013143:0.013123:0.013123:0.005719:0.012604:0.009236:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.006100:0.010660:0.010660:0.014913:0.006100:0.013143:0.011738:0.013181:0.006100:0.010660:0.010660:0.014913:0.005330:0.005330
the  complete response  rate is 50% and :@0.084242:0.161438:0.480513:0.161438:0.480513:0.145682:0.084242:0.145682:0.006523:0.011738:0.012508:0.005330:0.004968:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.010314:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.004974:0.005792:0.013143:0.006523:0.012508:0.010314:0.003848:0.007466:0.010314:0.010660:0.010660:0.014913:0.010314:0.013143:0.011738:0.013181:0.005330
20% and the median survival is 16 and nine :@0.084242:0.177538:0.480476:0.177538:0.480476:0.161782:0.084242:0.161782:0.010660:0.010660:0.014913:0.004464:0.013143:0.011738:0.013181:0.004464:0.006523:0.011738:0.012508:0.004464:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.004464:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004478:0.003848:0.007466:0.004464:0.010660:0.010660:0.004464:0.013143:0.011738:0.013181:0.004464:0.011738:0.003848:0.011738:0.012508:0.005330
months respectively.:@0.084242:0.193638:0.274479:0.193638:0.274479:0.177882:0.084242:0.177882:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.005702:0.012508:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330
Patients will almost always relapse. Such :@0.102426:0.209738:0.480472:0.209738:0.480472:0.193982:0.102426:0.193982:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005471:0.015990:0.003848:0.003848:0.003848:0.005484:0.013143:0.003848:0.018049:0.012604:0.007466:0.006523:0.005471:0.013143:0.003848:0.015990:0.013143:0.010314:0.007466:0.005484:0.005713:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.005330:0.005484:0.009583:0.011699:0.012450:0.011738:0.005330
patients may be retreated with the origi-:@0.084242:0.225838:0.475161:0.225838:0.475161:0.210082:0.084242:0.210082:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007716:0.018049:0.013143:0.010314:0.007716:0.013123:0.012508:0.007716:0.005713:0.012508:0.006523:0.005707:0.012508:0.013143:0.006523:0.012508:0.013181:0.007716:0.015990:0.003848:0.006523:0.011738:0.007716:0.006523:0.011738:0.012508:0.007716:0.012604:0.005792:0.003848:0.012950:0.003848:0.006388
nal regimen if they  have been  off treat-:@0.084242:0.241938:0.475179:0.241938:0.475179:0.226182:0.084242:0.226182:0.011738:0.013143:0.003848:0.008640:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.008640:0.003848:0.006042:0.008640:0.006523:0.011738:0.012508:0.010314:0.005330:0.003300:0.011738:0.013143:0.010660:0.012508:0.008640:0.013123:0.012508:0.012508:0.011738:0.005330:0.003300:0.012604:0.006094:0.006042:0.008640:0.006523:0.005711:0.012508:0.013143:0.006523:0.006388
ment for three months. Alternatively, they :@0.084242:0.258038:0.480490:0.258038:0.480490:0.242282:0.084242:0.242282:0.018049:0.012508:0.011738:0.006523:0.006583:0.006042:0.012604:0.005792:0.006581:0.006523:0.011738:0.005707:0.012508:0.012508:0.006587:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.006579:0.014239:0.003848:0.006523:0.012508:0.006186:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330:0.006600:0.006523:0.011738:0.012508:0.010314:0.005330
may be treated with a regimen to which :@0.084242:0.274138:0.480495:0.274138:0.480495:0.258382:0.084242:0.258382:0.018049:0.013143:0.010314:0.007177:0.013123:0.012508:0.007177:0.006523:0.005711:0.012508:0.013143:0.006523:0.012508:0.013181:0.007177:0.015990:0.003848:0.006523:0.011738:0.007177:0.013143:0.007177:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007177:0.006523:0.012604:0.007177:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330
the  patient has not  been exposed, e.g., :@0.084242:0.290237:0.480517:0.290237:0.480517:0.274482:0.084242:0.274482:0.006523:0.011738:0.012508:0.005330:0.003375:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.008717:0.011738:0.013143:0.007466:0.008717:0.011738:0.012604:0.006523:0.005330:0.003375:0.013123:0.012508:0.012508:0.011738:0.008717:0.012508:0.009236:0.013123:0.012604:0.007466:0.012508:0.013181:0.005330:0.008717:0.012508:0.005330:0.012950:0.005330:0.005330:0.005330
CAV. Single-agent topotecan may also :@0.084242:0.306337:0.480482:0.306337:0.480482:0.290581:0.084242:0.290581:0.015644:0.011886:0.012063:0.005330:0.012123:0.009583:0.003848:0.011738:0.012950:0.003848:0.012508:0.006388:0.013143:0.012950:0.012508:0.011738:0.006523:0.012123:0.006523:0.012604:0.013123:0.012604:0.006523:0.012508:0.012450:0.013131:0.011738:0.012123:0.018049:0.013143:0.010314:0.012123:0.013143:0.003848:0.007466:0.012604:0.005330
be used with a response rate of approxi-:@0.084242:0.322437:0.475154:0.322437:0.475154:0.306681:0.084242:0.306681:0.013123:0.012508:0.007466:0.011699:0.007466:0.012508:0.013181:0.007466:0.015990:0.003848:0.006523:0.011738:0.007466:0.013143:0.007466:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007466:0.005792:0.013143:0.006523:0.012508:0.007466:0.012604:0.006042:0.007466:0.013143:0.013123:0.013123:0.005719:0.012604:0.009236:0.003848:0.006388
mately 30%.:@0.084242:0.338537:0.195521:0.338537:0.195521:0.322781:0.084242:0.322781:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330:0.010660:0.010660:0.014913:0.005330
CHEMOTHERAPY AND IRRADIATION:@0.084242:0.370979:0.442579:0.370979:0.442579:0.353164:0.084242:0.353164:0.016677:0.014539:0.011118:0.019242:0.017960:0.008980:0.014539:0.011118:0.012401:0.015822:0.011973:0.013256:0.005987:0.015822:0.015822:0.014966:0.005987:0.005987:0.012401:0.012401:0.015822:0.014966:0.005987:0.015822:0.008980:0.005987:0.017960:0.015822
There  is  a  small  but  significant  improve-:@0.084242:0.388220:0.475135:0.388220:0.475135:0.372464:0.084242:0.372464:0.008197:0.011738:0.012508:0.005703:0.012508:0.005330:0.005018:0.003848:0.007466:0.005330:0.005022:0.013143:0.005330:0.005022:0.007466:0.018049:0.013143:0.003848:0.003848:0.005330:0.005028:0.013123:0.011699:0.006523:0.005330:0.005018:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.005330:0.005016:0.003848:0.018049:0.013123:0.005717:0.012604:0.010660:0.012508:0.006388
ment  in survival in patients who  receive :@0.084242:0.404320:0.480488:0.404320:0.480488:0.388564:0.084242:0.388564:0.018049:0.012508:0.011738:0.006523:0.005330:0.004395:0.003848:0.011738:0.009737:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013154:0.003848:0.009737:0.003848:0.011738:0.009737:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.009737:0.015990:0.011738:0.012604:0.005330:0.004395:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.005330
concurrent  chest irradiation,  although :@0.084242:0.420420:0.480501:0.420420:0.480501:0.404664:0.084242:0.404664:0.012450:0.012604:0.011738:0.012450:0.011699:0.005792:0.005700:0.012508:0.011738:0.006523:0.005330:0.012667:0.012450:0.011738:0.012508:0.007466:0.006523:0.018011:0.003848:0.005792:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330:0.012671:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005330
this results in an increase in oesophagitis. :@0.084242:0.436520:0.480507:0.436520:0.480507:0.420764:0.084242:0.420764:0.006523:0.011738:0.003848:0.007466:0.007928:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.007928:0.003848:0.011738:0.007928:0.013143:0.011738:0.007918:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007928:0.003848:0.011738:0.007928:0.012604:0.012508:0.007466:0.012604:0.013123:0.011738:0.013143:0.012950:0.003848:0.006523:0.003848:0.007466:0.005330:0.005330
It should therefore be administered to LD :@0.084242:0.452620:0.480480:0.452620:0.480480:0.436864:0.084242:0.436864:0.004349:0.006523:0.007331:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.007331:0.006523:0.011738:0.012508:0.005705:0.012508:0.006042:0.012604:0.005707:0.012508:0.007331:0.013123:0.012508:0.007331:0.013143:0.013181:0.018049:0.003848:0.011738:0.003848:0.007466:0.006523:0.012508:0.005711:0.012508:0.013181:0.007331:0.006523:0.012604:0.007331:0.008890:0.014316:0.005330
patients with good PS.:@0.084242:0.468720:0.290848:0.468720:0.290848:0.452964:0.084242:0.452964:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.012950:0.012604:0.012604:0.013181:0.005330:0.011392:0.009583:0.005330
SCLC is associated with a high incidence :@0.102426:0.484820:0.480492:0.484820:0.480492:0.469064:0.102426:0.469064:0.009583:0.015644:0.008890:0.015644:0.003925:0.003848:0.007466:0.003925:0.013143:0.007466:0.007466:0.012604:0.012450:0.003848:0.013143:0.006523:0.012508:0.013181:0.003925:0.015990:0.003848:0.006523:0.011738:0.003925:0.013143:0.003925:0.011738:0.003848:0.012950:0.011738:0.003916:0.003848:0.011738:0.012450:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.005330
of  brain metastases. Prophylactic cranial :@0.084242:0.500919:0.480486:0.500919:0.480486:0.485163:0.084242:0.485163:0.012604:0.006042:0.005330:0.003011:0.013123:0.005792:0.013143:0.003848:0.011738:0.008351:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.012508:0.007466:0.005330:0.008351:0.011392:0.005709:0.012604:0.013123:0.011738:0.010314:0.003848:0.013143:0.012450:0.006523:0.003848:0.012450:0.008351:0.012450:0.005792:0.013143:0.011738:0.003848:0.013143:0.003848:0.005330
irradiation decreases this relapse rate and :@0.084242:0.517019:0.480492:0.517019:0.480492:0.501263:0.084242:0.501263:0.003848:0.005792:0.005792:0.013143:0.013181:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.005317:0.013181:0.012508:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.005330:0.006523:0.011738:0.003848:0.007466:0.005319:0.005713:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.005330:0.005792:0.013143:0.006523:0.012508:0.005311:0.013143:0.011738:0.013181:0.005330
increases the three-year survival  rate by :@0.084242:0.533119:0.480474:0.533119:0.480474:0.517363:0.084242:0.517363:0.003848:0.011738:0.012450:0.005713:0.012508:0.013143:0.007466:0.012508:0.007466:0.009525:0.006523:0.011738:0.012508:0.009525:0.006523:0.011738:0.005711:0.012508:0.012508:0.006388:0.010314:0.012508:0.013143:0.005792:0.009525:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.004212:0.005792:0.013143:0.006523:0.012508:0.009525:0.013123:0.010314:0.005330
5%. It is indicated for good PS in patients :@0.084242:0.549365:0.480472:0.549365:0.480472:0.533609:0.084242:0.533609:0.010660:0.014913:0.005330:0.007524:0.004349:0.006523:0.007524:0.003848:0.007466:0.007524:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.007524:0.006042:0.012604:0.005792:0.007524:0.012950:0.012604:0.012604:0.013181:0.007514:0.011392:0.009583:0.007524:0.003848:0.011738:0.007524:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
who  achieve a complete  response  to :@0.084242:0.565610:0.480499:0.565610:0.480499:0.549854:0.084242:0.549854:0.015990:0.011738:0.012604:0.005330:0.008009:0.013143:0.012450:0.011738:0.003848:0.012508:0.010660:0.012508:0.013354:0.013143:0.013354:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.012508:0.005330:0.008011:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.008014:0.006523:0.012604:0.005330
chemotherapy.:@0.084242:0.581855:0.230061:0.581855:0.230061:0.566100:0.084242:0.566100:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
23:@0.230045:0.576177:0.242475:0.576177:0.242475:0.566991:0.230045:0.566991:0.006215:0.006215
REFERRAL:@0.084242:0.614926:0.188665:0.614926:0.188665:0.595329:0.084242:0.595329:0.013641:0.012230:0.011289:0.012230:0.013641:0.013641:0.017404:0.010348
Patients  who  present  with  oncological :@0.084242:0.633461:0.480486:0.633461:0.480486:0.617705:0.084242:0.617705:0.011392:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.009088:0.015990:0.011738:0.012604:0.005330:0.009086:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.005330:0.009086:0.015990:0.003848:0.006523:0.011738:0.005330:0.009092:0.012604:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.012450:0.013143:0.003848:0.005330
emergencies such as superior mediastinal :@0.084242:0.649706:0.480474:0.649706:0.480474:0.633950:0.084242:0.633950:0.012508:0.018049:0.012508:0.005804:0.012950:0.012508:0.011738:0.012450:0.003848:0.012508:0.007466:0.006119:0.007466:0.011699:0.012450:0.011738:0.006119:0.013143:0.007466:0.006119:0.007466:0.011699:0.013123:0.012508:0.005792:0.003848:0.012604:0.005792:0.006119:0.018049:0.012508:0.013181:0.003848:0.013143:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.005330
syndrome,  febrile neutropaenia and spi-:@0.084242:0.665952:0.475152:0.665952:0.475152:0.650196:0.084242:0.650196:0.007466:0.010314:0.011738:0.013181:0.005717:0.012604:0.018049:0.012508:0.005330:0.005330:0.004451:0.006042:0.012508:0.013123:0.005792:0.003848:0.003848:0.012508:0.009794:0.011738:0.012508:0.011699:0.006523:0.005703:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.009794:0.013143:0.011738:0.013181:0.009794:0.007466:0.013123:0.003852:0.006388
nal cord compression require urgent refer-:@0.084242:0.682197:0.475152:0.682197:0.475152:0.666441:0.084242:0.666441:0.011738:0.013143:0.003848:0.005090:0.012450:0.012604:0.005671:0.013181:0.005088:0.012450:0.012604:0.018049:0.013123:0.005711:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005088:0.005713:0.012508:0.013123:0.011699:0.003848:0.005715:0.012508:0.005086:0.011699:0.005804:0.012950:0.012508:0.011738:0.006523:0.005078:0.005713:0.012508:0.006042:0.012508:0.005784:0.006388
ral. The severe toxicities of therapy should :@0.084242:0.698442:0.480513:0.698442:0.480513:0.682686:0.084242:0.682686:0.005792:0.013143:0.003848:0.005330:0.006312:0.008197:0.011738:0.012508:0.006296:0.007466:0.012508:0.010660:0.012508:0.005715:0.012508:0.006312:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.003848:0.012508:0.007466:0.006312:0.012604:0.006042:0.006300:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.006312:0.007466:0.011738:0.012604:0.011699:0.003848:0.013181:0.005330
be managed by an oncologist.:@0.084242:0.714979:0.376188:0.714979:0.376188:0.699223:0.084242:0.699223:0.013123:0.012508:0.005330:0.018049:0.013143:0.011738:0.013143:0.012950:0.012508:0.013181:0.005330:0.013123:0.010314:0.005330:0.013143:0.011738:0.005330:0.012604:0.011738:0.012450:0.012604:0.003848:0.012604:0.012950:0.003848:0.007466:0.006523:0.005330
REFERENCES:@0.084242:0.745115:0.195079:0.745115:0.195079:0.729081:0.084242:0.729081:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084242:0.762188:0.103194:0.762188:0.103194:0.748183:0.084242:0.748183:0.009476:0.004738:0.004738
 Jemal A, :@0.120589:0.762188:0.198216:0.762188:0.198216:0.748183:0.120589:0.748183:0.000000:0.008244:0.011118:0.016044:0.011682:0.003421:0.004984:0.012657:0.004738:0.004738
et al:@0.198448:0.762188:0.235447:0.762188:0.235447:0.748183:0.198448:0.748183:0.011118:0.005798:0.004979:0.011682:0.003421
. Global cancer statistics. :@0.235447:0.762188:0.448331:0.762188:0.448331:0.748183:0.235447:0.748183:0.004738:0.004981:0.014915:0.003421:0.011203:0.011665:0.011682:0.003421:0.004994:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004977:0.006636:0.005798:0.011682:0.005798:0.003421:0.006636:0.005798:0.003421:0.011067:0.006636:0.004738:0.004738
CA :@0.448588:0.762188:0.479888:0.762188:0.479888:0.748183:0.448588:0.748183:0.013906:0.012657:0.004738
Cancer J Clin:@0.120589:0.776664:0.232845:0.776664:0.232845:0.762658:0.120589:0.762658:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434
. 2011;61:69-90.:@0.232828:0.776664:0.356954:0.776664:0.356954:0.762658:0.232828:0.762658:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
2. :@0.084225:0.791139:0.103177:0.791139:0.103177:0.777134:0.084225:0.777134:0.009476:0.004738:0.004738
 National Lung Screening  Trial Research :@0.120572:0.791139:0.479888:0.791139:0.479888:0.777134:0.120572:0.777134:0.000000:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.013359:0.007902:0.010399:0.010434:0.011511:0.013359:0.008518:0.011067:0.005078:0.011118:0.011118:0.010434:0.003421:0.010434:0.011511:0.004738:0.008610:0.006773:0.005148:0.003421:0.011682:0.003421:0.013359:0.010382:0.011118:0.006636:0.011118:0.011682:0.005029:0.011067:0.010434:0.004738
Team. Reduced lung-cancer mortality with :@0.120572:0.805615:0.479880:0.805615:0.479880:0.791610:0.120572:0.791610:0.006448:0.011118:0.011682:0.016044:0.004738:0.004878:0.010382:0.011118:0.011716:0.010399:0.011067:0.011118:0.011716:0.004878:0.003421:0.010399:0.010434:0.011511:0.005679:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004873:0.016044:0.011203:0.005140:0.005798:0.011682:0.003421:0.003421:0.005798:0.009168:0.004892:0.014214:0.003421:0.005798:0.010434:0.004738
low-dose computed tomographic screen-:@0.120572:0.820091:0.475137:0.820091:0.475137:0.806085:0.120572:0.806085:0.003421:0.011203:0.014214:0.005679:0.011716:0.011203:0.006636:0.011118:0.006688:0.011067:0.011203:0.016044:0.011665:0.010399:0.005798:0.011118:0.011716:0.006688:0.005798:0.011203:0.016044:0.011203:0.011511:0.005148:0.011682:0.011665:0.010434:0.003421:0.011067:0.006679:0.006636:0.011067:0.005080:0.011118:0.011118:0.010434:0.005679
ing.:@0.120572:0.834566:0.150676:0.834566:0.150676:0.820561:0.120572:0.820561:0.003421:0.010434:0.011511:0.004738
  New  England  Journal  of  Medicine.:@0.150676:0.834566:0.475139:0.834566:0.475139:0.820561:0.150676:0.820561:0.004738:0.006915:0.012657:0.011118:0.014214:0.004738:0.006910:0.009168:0.010434:0.011511:0.003421:0.011682:0.010434:0.011716:0.004738:0.006917:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738:0.006908:0.011203:0.005371:0.004738:0.006910:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118:0.004738
 :@0.475139:0.834566:0.479877:0.834566:0.479877:0.820561:0.475139:0.820561:0.004738
2011;365:395-409.:@0.120572:0.849042:0.263650:0.849042:0.263650:0.835037:0.120572:0.835037:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
3 :@0.084225:0.863517:0.098439:0.863517:0.098439:0.849512:0.084225:0.849512:0.009476:0.004738
 Ryan C, Burke L. Pathology of lung tumours.:@0.120569:0.863517:0.475156:0.863517:0.475156:0.849512:0.120569:0.849512:0.000000:0.010931:0.009171:0.011684:0.010430:0.004721:0.013906:0.004734:0.004721:0.009821:0.010398:0.005145:0.008585:0.011116:0.004721:0.007901:0.004734:0.004721:0.009955:0.011511:0.005627:0.010263:0.011032:0.003250:0.011032:0.011340:0.008997:0.004551:0.011032:0.005200:0.004551:0.003250:0.010228:0.010263:0.011340:0.004550:0.005627:0.010228:0.015873:0.011032:0.010228:0.004977:0.006465:0.004738
 :@0.475128:0.863517:0.479866:0.863517:0.479866:0.849512:0.475128:0.849512:0.004738
Surgery (Oxford):@0.120572:0.877993:0.255457:0.877993:0.255457:0.863988:0.120572:0.863988:0.008518:0.010399:0.005148:0.011511:0.011118:0.005148:0.009168:0.004738:0.006312:0.014864:0.008210:0.005371:0.011203:0.005148:0.011716:0.006312
. 2017 May:35:234-242.:@0.255440:0.877993:0.439825:0.877993:0.439825:0.863988:0.255440:0.863988:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.009168:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
4 :@0.084225:0.892469:0.098439:0.892469:0.098439:0.878464:0.084225:0.878464:0.009476:0.004738
  Chen,  Y-M.  Immune  checkpoint  inhibitors :@0.120572:0.892469:0.479875:0.892469:0.479875:0.878464:0.120572:0.878464:0.004738:-0.004738:0.013906:0.010434:0.011118:0.010434:0.004738:0.004738:0.003609:0.010126:0.005679:0.015719:0.004738:0.004738:0.003611:0.003866:0.016044:0.016044:0.010399:0.010434:0.011118:0.004738:0.003612:0.011067:0.010434:0.011118:0.011067:0.008586:0.011665:0.011203:0.003421:0.010434:0.005798:0.004738:0.003612:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.011203:0.005148:0.006636:0.004738
for  non-small cell lung  cancer  treatment. :@0.120572:0.906944:0.479897:0.906944:0.479897:0.892939:0.120572:0.892939:0.005371:0.011203:0.005148:0.004738:0.003453:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.008210:0.011067:0.011118:0.003421:0.003421:0.008210:0.003421:0.010399:0.010434:0.011511:0.004738:0.003459:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003453:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738
Journal of the Chinese Medical Associa-:@0.120572:0.921420:0.475145:0.921420:0.475145:0.907415:0.120572:0.907415:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.009185:0.011203:0.005371:0.009185:0.005798:0.010434:0.011118:0.009185:0.013906:0.010434:0.003421:0.010434:0.011118:0.006636:0.011118:0.009185:0.015719:0.011118:0.011716:0.003421:0.011067:0.011682:0.003421:0.009185:0.012657:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005679
tion. :@0.120572:0.935896:0.160904:0.935896:0.160904:0.921890:0.120572:0.921890:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738
2017;80:7-14.:@0.160887:0.935896:0.266062:0.935896:0.266062:0.921890:0.160887:0.921890:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.009476:0.004738
5. :@0.523619:0.094721:0.542571:0.094721:0.542571:0.080715:0.523619:0.080715:0.009479:0.004734:0.004738
  Abratt RP, Morgan GM, Silvestri G, :@0.559966:0.094721:0.837912:0.094721:0.837912:0.080715:0.559966:0.080715:0.004738:-0.004738:0.012315:0.011323:0.004806:0.011340:0.005456:0.005456:0.005910:0.010040:0.007676:0.004396:0.005910:0.015377:0.010861:0.004820:0.011169:0.011340:0.010092:0.005910:0.014573:0.015377:0.004396:0.005910:0.008176:0.003079:0.003079:0.009134:0.010776:0.006294:0.005456:0.004806:0.003079:0.005908:0.014573:0.004396:0.004738
et al:@0.839075:0.094721:0.875976:0.094721:0.875976:0.080715:0.839075:0.080715:0.010776:0.005456:0.005908:0.011340:0.003421
. Pul-:@0.875634:0.094721:0.914538:0.094721:0.914538:0.080715:0.875634:0.080715:0.004396:0.005910:0.009784:0.010057:0.003079:0.005679
monary complications of radiation therapy. :@0.559966:0.108879:0.919274:0.108879:0.919274:0.094874:0.559966:0.094874:0.015702:0.010861:0.010092:0.011340:0.004806:0.008826:0.006414:0.010724:0.010861:0.015702:0.011323:0.003079:0.003079:0.010724:0.011340:0.005456:0.003079:0.010861:0.010092:0.006294:0.006414:0.010861:0.005029:0.006414:0.004806:0.011340:0.011374:0.003079:0.011340:0.005456:0.003079:0.010861:0.010092:0.006414:0.005456:0.010092:0.010776:0.004806:0.011340:0.011323:0.008826:0.004734:0.004738
Clinics In Chest Med.:@0.559966:0.123037:0.725126:0.123037:0.725126:0.109032:0.559966:0.109032:0.013564:0.003079:0.003079:0.010092:0.003079:0.010724:0.006294:0.004396:0.003523:0.010092:0.004396:0.013564:0.010092:0.010776:0.006294:0.005456:0.004396:0.015377:0.010776:0.011374:0.004738
 2004;25:165-175.:@0.724784:0.123037:0.857650:0.123037:0.857650:0.109032:0.724784:0.109032:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.004738
6. :@0.523619:0.137195:0.542571:0.137195:0.542571:0.123190:0.523619:0.123190:0.009476:0.004738:0.004738
  Rami-Porta Asamura, H, Travis WD. :@0.559966:0.137195:0.850381:0.137195:0.850381:0.123190:0.559966:0.123190:0.004738:-0.004738:0.010382:0.011682:0.016044:0.003421:0.005679:0.010126:0.011203:0.005148:0.005781:0.011682:0.005525:0.012657:0.006636:0.011682:0.016044:0.010399:0.005148:0.011682:0.004738:0.005525:0.011682:0.004738:0.005525:0.006773:0.005148:0.011682:0.009476:0.003421:0.006636:0.005525:0.016420:0.012726:0.004738:0.004738
Cancer :@0.851168:0.137195:0.919260:0.137195:0.919260:0.123190:0.851168:0.123190:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
Staging Manual:@0.559966:0.151506:0.690698:0.151506:0.690698:0.137501:0.559966:0.137501:0.008518:0.005798:0.011682:0.011511:0.003421:0.010434:0.011511:0.004519:0.015719:0.011682:0.010434:0.010399:0.011682:0.003421
. 8th ed. New York: Springer :@0.690698:0.151506:0.919270:0.151506:0.919270:0.137501:0.690698:0.137501:0.004738:0.004519:0.009476:0.005798:0.010434:0.004521:0.011118:0.011716:0.004738:0.004519:0.012657:0.011118:0.014214:0.004517:0.008602:0.011203:0.005148:0.008578:0.004738:0.004519:0.008518:0.011665:0.005148:0.003421:0.010434:0.011511:0.011118:0.005148:0.004738
International Publishing; 2016.:@0.559966:0.165817:0.803079:0.165817:0.803079:0.151812:0.559966:0.151812:0.003866:0.010434:0.005798:0.011118:0.005499:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.003421:0.010434:0.011511:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
7. :@0.523619:0.180128:0.542571:0.180128:0.542571:0.166123:0.523619:0.166123:0.009476:0.004738:0.004738
  Nyman  J, :@0.559966:0.180128:0.647920:0.180128:0.647920:0.166123:0.559966:0.166123:0.004738:-0.004738:0.012657:0.009168:0.016044:0.011682:0.010434:0.004738:0.005511:0.008244:0.004738:0.004738
et  al:@0.653424:0.180128:0.695691:0.180128:0.695691:0.166123:0.653424:0.166123:0.011118:0.005798:0.004738:0.005509:0.011682:0.003421
.  SPACE  –  a  randomized :@0.695691:0.180128:0.919262:0.180128:0.919262:0.166123:0.695691:0.166123:0.004738:0.004738:0.005513:0.008518:0.008853:0.012657:0.013906:0.009168:0.004738:0.005511:0.008552:0.004738:0.005514:0.011682:0.004738:0.005516:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004738
study of SBRT vs  conventional fractionat-:@0.559966:0.194439:0.914534:0.194439:0.914534:0.180434:0.559966:0.180434:0.006636:0.005798:0.010399:0.011716:0.009168:0.009014:0.011203:0.005371:0.009014:0.008518:0.009818:0.010487:0.007286:0.009014:0.009476:0.006636:0.004738:0.004286:0.011067:0.011203:0.010434:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.009014:0.005371:0.005148:0.011682:0.011067:0.005798:0.003421:0.011203:0.010434:0.011682:0.005798:0.005679
ed radiotherapy in medically inoperable :@0.559966:0.208750:0.919277:0.208750:0.919277:0.194745:0.559966:0.194745:0.011118:0.011716:0.009442:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.009442:0.003421:0.010434:0.009442:0.016044:0.011118:0.011716:0.003421:0.011067:0.011682:0.003421:0.003421:0.009168:0.009442:0.003421:0.010434:0.011203:0.011665:0.011118:0.005148:0.011682:0.011665:0.003421:0.011118:0.004738
stage  INSCLC. :@0.559966:0.223061:0.686545:0.223061:0.686545:0.209056:0.559966:0.209056:0.006636:0.005798:0.011682:0.011511:0.011118:0.004738:0.004864:0.003866:0.012657:0.008518:0.013906:0.007902:0.013906:0.004738:0.004738
Radiotherapy  and  Oncol-:@0.691396:0.223061:0.914521:0.223061:0.914521:0.209056:0.691396:0.209056:0.010382:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004864:0.011682:0.010434:0.011716:0.004738:0.004866:0.014864:0.010434:0.011067:0.011203:0.003421:0.005679
ogy:@0.559966:0.237372:0.591848:0.237372:0.591848:0.223367:0.559966:0.223367:0.011203:0.011511:0.009168
. 2016;121(1):1-8.:@0.591848:0.237372:0.728598:0.237372:0.728598:0.223367:0.591848:0.223367:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.005679:0.009476:0.004738
8. :@0.523619:0.251683:0.542571:0.251683:0.542571:0.237678:0.523619:0.237678:0.009476:0.004738:0.004738
  Taiol E, :@0.559966:0.251683:0.620243:0.251683:0.620243:0.237678:0.559966:0.237678:0.004738:-0.004738:0.006397:0.011682:0.003421:0.011203:0.003421:0.005509:0.009168:0.004738:0.004738
et al:@0.621011:0.251683:0.658538:0.251683:0.658538:0.237678:0.621011:0.237678:0.011118:0.005798:0.005508:0.011682:0.003421
. Second primary lung cancers :@0.658538:0.251683:0.919284:0.251683:0.919284:0.237678:0.658538:0.237678:0.004738:0.005508:0.008518:0.011118:0.011067:0.011203:0.010434:0.011716:0.005497:0.011665:0.005148:0.003421:0.016044:0.011682:0.005148:0.009168:0.005508:0.003421:0.010399:0.010434:0.011511:0.005508:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006636:0.004738
demonstrate  better  survival with  surgery :@0.559966:0.265994:0.919267:0.265994:0.919267:0.251989:0.559966:0.251989:0.011716:0.011118:0.016044:0.011203:0.010434:0.006636:0.005798:0.005148:0.011682:0.005798:0.011118:0.004738:0.006390:0.011665:0.011118:0.005798:0.005798:0.011118:0.005148:0.004738:0.006392:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.011152:0.014214:0.003421:0.005798:0.010434:0.004738:0.006400:0.006636:0.010399:0.005164:0.011511:0.011118:0.005148:0.009168:0.004738
than radiation seminars. :@0.559966:0.280305:0.767818:0.280305:0.767818:0.266300:0.559966:0.266300:0.005798:0.010434:0.011682:0.010434:0.007201:0.005148:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.007201:0.006636:0.011118:0.016044:0.003421:0.010434:0.011682:0.005148:0.006636:0.004738:0.004738
Thoracic Surgery.:@0.770281:0.280305:0.914531:0.280305:0.914531:0.266300:0.770281:0.266300:0.007286:0.010434:0.011203:0.005148:0.011682:0.011067:0.003421:0.011058:0.007201:0.008518:0.010399:0.005148:0.011511:0.011118:0.005148:0.009168:0.004738
 :@0.914522:0.280305:0.919260:0.280305:0.919260:0.266300:0.914522:0.266300:0.004738
2016;28:195-200.:@0.559966:0.294616:0.693568:0.294616:0.693568:0.280611:0.559966:0.280611:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
9. :@0.523619:0.308927:0.542571:0.308927:0.542571:0.294922:0.523619:0.294922:0.009476:0.004738:0.004738
  Arriagada  R, :@0.559966:0.308927:0.673707:0.308927:0.673707:0.294922:0.559966:0.294922:0.004738:-0.004738:0.012657:0.005148:0.005148:0.003421:0.011682:0.011511:0.011682:0.011716:0.011682:0.004738:0.004495:0.010382:0.004738:0.004738
et al.:@0.678208:0.308927:0.724202:0.308927:0.724202:0.294922:0.678208:0.294922:0.011118:0.005798:0.009236:0.011682:0.003421:0.004738
 Cisplatin-based  adju-:@0.724202:0.308927:0.914527:0.308927:0.914527:0.294922:0.724202:0.294922:0.009236:0.013906:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.004738:0.004521:0.011682:0.011716:0.003472:0.010399:0.005679
vant chemotherapy in patients with com-:@0.559966:0.323238:0.914524:0.323238:0.914524:0.309233:0.559966:0.309233:0.009476:0.011682:0.010434:0.005798:0.006808:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011667:0.011665:0.009168:0.006808:0.003421:0.010434:0.006808:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006808:0.014214:0.003421:0.005798:0.010434:0.006808:0.011067:0.011203:0.016044:0.005679
pletely resected  non-small-cell lung  can-:@0.559966:0.337549:0.914533:0.337549:0.914533:0.323544:0.559966:0.323544:0.011665:0.003421:0.011118:0.005798:0.011118:0.003421:0.009168:0.009236:0.005078:0.011118:0.006636:0.011118:0.011067:0.005798:0.011118:0.011716:0.004738:0.004490:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.009236:0.003421:0.010399:0.010434:0.011511:0.004738:0.004485:0.011067:0.011682:0.010434:0.005679
cer. :@0.559966:0.351860:0.595516:0.351860:0.595516:0.337855:0.559966:0.337855:0.011067:0.011118:0.003890:0.004738:0.004738
N Engl J Med:@0.595516:0.351860:0.703718:0.351860:0.703718:0.337855:0.595516:0.337855:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2004;350:351-360.:@0.703694:0.351860:0.856248:0.351860:0.856248:0.337855:0.703694:0.337855:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10.   Strauss  GM, :@0.523619:0.366171:0.659229:0.366171:0.659229:0.352166:0.523619:0.352166:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.008005:0.005285:0.004635:0.011169:0.009886:0.006123:0.006123:0.004738:0.004733:0.014402:0.015206:0.004225:0.004738
et al.:@0.663960:0.366171:0.708141:0.366171:0.708141:0.352166:0.663960:0.352166:0.010605:0.005285:0.009476:0.011169:0.002908:0.004738
 Adjuvant paclitaxel plus :@0.707628:0.366171:0.919264:0.366171:0.919264:0.352166:0.707628:0.352166:0.009476:0.012144:0.011203:0.002959:0.009886:0.008963:0.011169:0.009921:0.005285:0.009476:0.011152:0.011169:0.010553:0.002908:0.002908:0.005285:0.011169:0.007697:0.010605:0.002908:0.009476:0.011152:0.002908:0.009886:0.006640:0.004738
carboplatin  compared  with  observation  in :@0.559966:0.380482:0.919264:0.380482:0.919264:0.366477:0.559966:0.366477:0.010553:0.011169:0.004635:0.011152:0.010690:0.011152:0.002908:0.011169:0.005285:0.002908:0.009921:0.004738:0.005326:0.010553:0.010690:0.015531:0.011152:0.011169:0.004563:0.010605:0.011203:0.004738:0.005326:0.013701:0.002908:0.005285:0.009921:0.004738:0.005326:0.010690:0.011152:0.006123:0.010605:0.004635:0.008963:0.011169:0.005285:0.002908:0.010690:0.009921:0.004738:0.005325:0.002908:0.010432:0.004738
stage IB non-small-cell lung cancer: CALGB :@0.559966:0.394793:0.919281:0.394793:0.919281:0.380788:0.559966:0.380788:0.006123:0.005285:0.011169:0.010998:0.010605:0.007748:0.003352:0.009305:0.007748:0.009921:0.010690:0.009921:0.005166:0.006123:0.015531:0.011169:0.002908:0.002908:0.005166:0.010553:0.010605:0.002908:0.002908:0.007748:0.002908:0.009886:0.009921:0.010998:0.007748:0.010553:0.011169:0.009921:0.010553:0.010605:0.004635:0.004225:0.007748:0.013393:0.012144:0.007389:0.014402:0.009821:0.004738
9633 with the Cancer and Leukemia Group :@0.559966:0.409104:0.919277:0.409104:0.919277:0.395099:0.559966:0.395099:0.008963:0.008963:0.008963:0.008963:0.006859:0.013701:0.002908:0.005285:0.009921:0.006859:0.005285:0.009921:0.010605:0.006859:0.013393:0.011169:0.009921:0.010553:0.010605:0.004635:0.006859:0.011169:0.009921:0.011203:0.006859:0.007389:0.010605:0.009886:0.008073:0.010605:0.015531:0.002908:0.011169:0.006859:0.014402:0.004565:0.010690:0.009886:0.011667:0.004738
B, Radiation Therapy Oncology Group, and :@0.559966:0.423415:0.919276:0.423415:0.919276:0.409410:0.559966:0.409410:0.009305:0.004225:0.007304:0.009869:0.011169:0.011203:0.002908:0.011169:0.005285:0.002908:0.010690:0.009921:0.007304:0.006773:0.009921:0.010605:0.004635:0.011169:0.011152:0.008655:0.007304:0.014351:0.009921:0.010553:0.010690:0.002908:0.010690:0.010998:0.008655:0.007304:0.014402:0.004565:0.010690:0.009886:0.011152:0.004225:0.007304:0.011169:0.009921:0.011716:0.004738
North Central Cancer Treatment Group Study :@0.559966:0.437726:0.919311:0.437726:0.919311:0.423721:0.559966:0.423721:0.012144:0.010690:0.004635:0.005285:0.009921:0.004054:0.013393:0.010605:0.009921:0.005285:0.004635:0.011169:0.002908:0.004054:0.013393:0.011169:0.009921:0.010553:0.010605:0.004635:0.004054:0.006260:0.004565:0.010605:0.011169:0.005285:0.015531:0.010605:0.009921:0.005285:0.004054:0.014402:0.004565:0.010690:0.009886:0.011152:0.004054:0.008005:0.005285:0.009886:0.011203:0.009171:0.004738
Groups. :@0.559966:0.452038:0.625746:0.452038:0.625746:0.438032:0.559966:0.438032:0.014402:0.004563:0.010690:0.009886:0.011152:0.006123:0.004225:0.004738
J Clin Oncol:@0.625236:0.452038:0.719481:0.452038:0.719481:0.438032:0.625236:0.438032:0.007731:0.004225:0.013393:0.002908:0.002908:0.009921:0.004225:0.014351:0.009921:0.010553:0.010690:0.003421
. 2008;26:5043-5051.:@0.718968:0.452038:0.871248:0.452038:0.871248:0.438032:0.718968:0.438032:0.004225:0.004225:0.008963:0.008963:0.008963:0.008963:0.004225:0.008963:0.008963:0.004225:0.008963:0.008963:0.008963:0.008963:0.005166:0.008963:0.008963:0.008963:0.008963:0.004738
11.   Furuse K, :@0.523619:0.466784:0.636210:0.466784:0.636210:0.452778:0.523619:0.452778:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008296:0.010399:0.005148:0.010399:0.006636:0.011118:0.004663:0.010109:0.004738:0.004738
et al.:@0.636132:0.466784:0.677558:0.466784:0.677558:0.452778:0.636132:0.452778:0.011118:0.005798:0.004669:0.011682:0.003421:0.004738
 Phase III study of concurrent:@0.677558:0.466784:0.914526:0.466784:0.914526:0.452778:0.677558:0.452778:0.004669:0.010126:0.010434:0.011682:0.006636:0.011118:0.004669:0.003866:0.003866:0.003866:0.004669:0.006636:0.005798:0.010399:0.011716:0.009168:0.004669:0.011203:0.005371:0.004669:0.011067:0.011203:0.010434:0.011067:0.010399:0.005148:0.005066:0.011118:0.010434:0.005798
 :@0.914526:0.466784:0.919264:0.466784:0.919264:0.452778:0.914526:0.452778:0.004738
versus:@0.559966:0.481530:0.609380:0.481530:0.609380:0.467524:0.559966:0.467524:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636
 sequential thoracic  radiotherapy :@0.609380:0.481530:0.919267:0.481530:0.919267:0.467524:0.609380:0.467524:0.013820:0.006636:0.011118:0.011665:0.010399:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.013820:0.005798:0.010434:0.011203:0.005148:0.011682:0.011067:0.003421:0.011067:0.004738:0.009072:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738
in  combination  with  mitomycin,  vindes-:@0.559966:0.496276:0.914524:0.496276:0.914524:0.482271:0.559966:0.482271:0.003421:0.010434:0.004738:0.007926:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.007923:0.014214:0.003421:0.005798:0.010434:0.004738:0.007924:0.016044:0.003421:0.005798:0.011203:0.016044:0.009168:0.011067:0.003421:0.010434:0.004738:0.004738:0.007923:0.009476:0.003421:0.010434:0.011716:0.011118:0.006636:0.005679
ine, and cisplatin in unresectable stage III :@0.559966:0.511022:0.919270:0.511022:0.919270:0.497017:0.559966:0.497017:0.003421:0.010434:0.011118:0.004738:0.006951:0.011682:0.010434:0.011716:0.006961:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.006961:0.003421:0.010434:0.006961:0.010399:0.010434:0.005075:0.011118:0.006636:0.011118:0.011067:0.005798:0.011682:0.011665:0.003421:0.011118:0.006961:0.006636:0.005798:0.011682:0.011511:0.011118:0.006953:0.003866:0.003866:0.003866:0.004738
non-small cell lung  cancer. :@0.559966:0.525768:0.798293:0.525768:0.798293:0.511763:0.559966:0.511763:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.008621:0.011067:0.011118:0.003421:0.003421:0.008621:0.003421:0.010399:0.010434:0.011511:0.004738:0.003871:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
J  Clin Oncol:@0.802147:0.525768:0.909791:0.525768:0.909791:0.511763:0.802147:0.511763:0.008244:0.004738:0.003872:0.013906:0.003421:0.003421:0.010434:0.008621:0.014864:0.010434:0.011067:0.011203:0.003421
. :@0.909791:0.525768:0.919267:0.525768:0.919267:0.511763:0.909791:0.511763:0.004738:0.004738
1999;17;2692-2699.:@0.559966:0.540514:0.712520:0.540514:0.712520:0.526509:0.559966:0.526509:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
12.   Albain KS, :@0.523619:0.555260:0.646365:0.555260:0.646365:0.541255:0.523619:0.541255:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.012657:0.003421:0.011665:0.011682:0.003421:0.010434:0.005017:0.010109:0.008518:0.004738:0.004738
et al.:@0.646634:0.555260:0.688403:0.555260:0.688403:0.541255:0.646634:0.541255:0.011118:0.005798:0.005012:0.011682:0.003421:0.004738
 Radiotherapy plus chemo-:@0.688403:0.555260:0.914522:0.555260:0.914522:0.541255:0.688403:0.541255:0.005012:0.010382:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005012:0.011665:0.003421:0.010399:0.006636:0.005012:0.011067:0.010434:0.011118:0.016044:0.011203:0.005679
therapy with or  without  surgical resection :@0.559966:0.570006:0.919272:0.570006:0.919272:0.556001:0.559966:0.556001:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.007782:0.014214:0.003421:0.005798:0.010434:0.007782:0.011203:0.005148:0.004738:0.003036:0.014214:0.003421:0.005798:0.010434:0.011203:0.010399:0.005798:0.004738:0.003036:0.006636:0.010399:0.005162:0.011511:0.003421:0.011067:0.011682:0.003421:0.007782:0.005078:0.011118:0.006636:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738
for stage III non-small-cell  lung cancer: a :@0.559966:0.584753:0.919270:0.584753:0.919270:0.570747:0.559966:0.570747:0.005371:0.011203:0.005148:0.008022:0.006636:0.005798:0.011682:0.011511:0.011118:0.008022:0.003866:0.003866:0.003866:0.008022:0.010434:0.011203:0.010434:0.005670:0.006636:0.016044:0.011682:0.003421:0.003421:0.005679:0.011067:0.011118:0.003421:0.003421:0.004738:0.003303:0.003421:0.010399:0.010434:0.011511:0.008022:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.008022:0.011682:0.004738
phase III randomised controlled trial. :@0.559966:0.599499:0.875991:0.599499:0.875991:0.585493:0.559966:0.585493:0.011665:0.010434:0.011682:0.006636:0.011118:0.007594:0.003866:0.003866:0.003866:0.007594:0.005148:0.011682:0.010434:0.011716:0.011203:0.016044:0.003421:0.006636:0.011118:0.011716:0.007594:0.011067:0.011203:0.010434:0.005798:0.005068:0.011203:0.003421:0.003421:0.011118:0.011716:0.007594:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Lan-:@0.878848:0.599499:0.914544:0.599499:0.914544:0.585493:0.878848:0.585493:0.007902:0.011682:0.010434:0.005679
cet:@0.559966:0.614245:0.587949:0.614245:0.587949:0.600239:0.559966:0.600239:0.011067:0.011118:0.005798
. 2009;374:379-386.:@0.587949:0.614245:0.740502:0.614245:0.740502:0.600239:0.587949:0.600239:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
13.   Schiller  JH, :@0.523619:0.628991:0.660346:0.628991:0.660346:0.614986:0.523619:0.614986:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.011067:0.010434:0.003421:0.003421:0.003421:0.011118:0.005148:0.004738:0.009693:0.008244:0.011682:0.004738:0.004738
et  al.:@0.670033:0.628991:0.721214:0.628991:0.721214:0.614986:0.670033:0.614986:0.011118:0.005798:0.004738:0.009686:0.011682:0.003421:0.004738
  Comparison  of  four :@0.721214:0.628991:0.919269:0.628991:0.919269:0.614986:0.721214:0.614986:0.004738:0.009690:0.013906:0.011203:0.016044:0.011665:0.011682:0.005148:0.003421:0.006636:0.011203:0.010434:0.004738:0.009688:0.011203:0.005371:0.004738:0.009686:0.005371:0.011203:0.010399:0.005148:0.004738
chemotherapy  regimens for advanced :@0.559966:0.643737:0.919265:0.643737:0.919265:0.629732:0.559966:0.629732:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.009825:0.005078:0.011118:0.011511:0.003421:0.016044:0.011118:0.010434:0.006636:0.014573:0.005371:0.011203:0.005148:0.014573:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.004738
non-small cell lung cancer. :@0.559966:0.658483:0.793069:0.658483:0.793069:0.644478:0.559966:0.644478:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.006876:0.011067:0.011118:0.003421:0.003421:0.006876:0.003421:0.010399:0.010434:0.011511:0.006876:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
N Engl J Med.:@0.795207:0.658483:0.914553:0.658483:0.914553:0.644478:0.795207:0.644478:0.012657:0.006867:0.009168:0.010434:0.011511:0.003421:0.006876:0.008244:0.006876:0.015719:0.011118:0.011716:0.004738
 :@0.914553:0.658483:0.919291:0.658483:0.919291:0.644478:0.914553:0.644478:0.004738
2002;346:92-98.:@0.559966:0.673229:0.684092:0.673229:0.684092:0.659224:0.559966:0.659224:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
14   Scagliotti GV, :@0.523619:0.687975:0.675299:0.687975:0.675299:0.673970:0.523619:0.673970:0.009476:0.009476:0.004738:0.012657:0.000000:0.008518:0.011067:0.011682:0.011511:0.003421:0.003421:0.011203:0.005798:0.005798:0.003421:0.004904:0.014915:0.010198:0.004738:0.004738
et al.:@0.675455:0.687975:0.717111:0.687975:0.717111:0.673970:0.675455:0.673970:0.011118:0.005798:0.004899:0.011682:0.003421:0.004738
 Phase III study compar-:@0.717111:0.687975:0.914538:0.687975:0.914538:0.673970:0.717111:0.673970:0.004909:0.010126:0.010434:0.011682:0.006636:0.011118:0.004900:0.003866:0.003866:0.003866:0.004909:0.006636:0.005798:0.010399:0.011716:0.009168:0.004909:0.011067:0.011203:0.016044:0.011665:0.011682:0.005148:0.005679
ing cisplatin plus gemcitabine with cisplatin :@0.559966:0.702721:0.919257:0.702721:0.919257:0.688716:0.559966:0.688716:0.003421:0.010434:0.011511:0.004160:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004173:0.011665:0.003421:0.010399:0.006636:0.004173:0.011511:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.004161:0.014214:0.003421:0.005798:0.010434:0.004161:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738
plus pemetrexed  in chemotherapy-naive :@0.559966:0.717467:0.919264:0.717467:0.919264:0.703462:0.559966:0.703462:0.011665:0.003421:0.010399:0.006636:0.009647:0.011665:0.011118:0.016044:0.011118:0.005798:0.005075:0.011118:0.008210:0.011118:0.011716:0.004738:0.004899:0.003421:0.010434:0.009647:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011667:0.011665:0.009168:0.005679:0.010434:0.011682:0.003421:0.009476:0.011118:0.004738
patients with advanced-stage non-small-:@0.559966:0.732214:0.914505:0.732214:0.914505:0.718208:0.559966:0.718208:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.009390:0.014214:0.003421:0.005798:0.010434:0.009390:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005679:0.006636:0.005798:0.011682:0.011511:0.011118:0.009390:0.010434:0.011203:0.010434:0.005679:0.006636:0.016044:0.011682:0.003421:0.003421:0.005679
cell lung cancer. :@0.559966:0.746960:0.722806:0.746960:0.722806:0.732954:0.559966:0.732954:0.011067:0.011118:0.003421:0.003421:0.014658:0.003421:0.010399:0.010434:0.011511:0.014658:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
J Clin Oncol:@0.732727:0.746960:0.852457:0.746960:0.852457:0.732954:0.732727:0.732954:0.008244:0.014658:0.013906:0.003421:0.003421:0.010434:0.014658:0.014864:0.010434:0.011067:0.011203:0.003421
. 2008; :@0.852457:0.746960:0.919233:0.746960:0.919233:0.732954:0.852457:0.732954:0.004738:0.014658:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
26:3543-3551.:@0.559966:0.761706:0.669879:0.761706:0.669879:0.747701:0.559966:0.747701:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
15.   Tsao  MS, :@0.523619:0.776452:0.638850:0.776452:0.638850:0.762447:0.523619:0.762447:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.006890:0.006636:0.011682:0.011203:0.004738:0.004021:0.015719:0.008518:0.004738:0.004738
et al.:@0.642871:0.776452:0.688385:0.776452:0.688385:0.762447:0.642871:0.762447:0.011118:0.005798:0.008757:0.011682:0.003421:0.004738
 Erlotinib in lung cancer –  :@0.688385:0.776452:0.919277:0.776452:0.919277:0.762447:0.688385:0.762447:0.008757:0.009168:0.005148:0.003421:0.011203:0.005798:0.003421:0.010434:0.003421:0.011665:0.008757:0.003421:0.010434:0.008757:0.003421:0.010399:0.010434:0.011511:0.008757:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.008757:0.008552:0.000000:0.004738
molecular and clinical  predictors of out-:@0.559983:0.791198:0.914555:0.791198:0.914555:0.777193:0.559983:0.777193:0.016044:0.011203:0.003421:0.011118:0.011067:0.010399:0.003421:0.011682:0.005148:0.009356:0.011682:0.010434:0.011716:0.009356:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.004634:0.011665:0.005080:0.011118:0.011716:0.003421:0.011067:0.005798:0.011203:0.005148:0.006636:0.009356:0.011203:0.005371:0.009356:0.011203:0.010399:0.005798:0.005679
come. :@0.559983:0.805944:0.618890:0.805944:0.618890:0.791939:0.559983:0.791939:0.011067:0.011203:0.016044:0.011118:0.004738:0.004738
N Engl J Med:@0.618873:0.805944:0.727076:0.805944:0.727076:0.791939:0.618873:0.791939:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2005; 353:133-144.:@0.727058:0.805944:0.884350:0.805944:0.884350:0.791939:0.727058:0.791939:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
16.   Ding PN,:@0.523619:0.820690:0.629367:0.820690:0.629367:0.806685:0.523619:0.806685:0.009479:0.009479:0.004731:0.004738:0.007914:0.000000:0.012555:0.003250:0.010263:0.011340:0.004820:0.009955:0.012486:0.004738
 et al.:@0.629196:0.820690:0.674916:0.820690:0.674916:0.806685:0.629196:0.806685:0.004823:0.010947:0.005627:0.004823:0.011511:0.003250:0.004738
 Risk of treatment-related tox-:@0.674745:0.820690:0.914562:0.820690:0.914562:0.806685:0.674745:0.806685:0.004823:0.010211:0.003250:0.006465:0.008415:0.004823:0.011032:0.005200:0.004823:0.005627:0.004907:0.010947:0.011511:0.005627:0.015873:0.010947:0.010263:0.005627:0.005508:0.004907:0.010947:0.003250:0.011511:0.005627:0.010947:0.011545:0.004823:0.005627:0.011032:0.008039:0.005679
icities from EGFR tyrosine kinase inhibitors: :@0.559966:0.835436:0.919234:0.835436:0.919234:0.821431:0.559966:0.821431:0.003250:0.010895:0.003250:0.005627:0.003250:0.010947:0.006465:0.008963:0.005200:0.004906:0.011032:0.015873:0.008963:0.008997:0.014744:0.008125:0.010211:0.008963:0.005627:0.008997:0.004906:0.011032:0.006465:0.003250:0.010263:0.010947:0.008963:0.008415:0.003250:0.010263:0.011511:0.006465:0.010947:0.008963:0.003250:0.010263:0.010263:0.003250:0.011494:0.003250:0.005627:0.011032:0.004977:0.006465:0.004736:0.004738
a meta-analysis of clinical trials of gefitinib, :@0.559966:0.850182:0.919245:0.850182:0.919245:0.836177:0.559966:0.836177:0.011511:0.006447:0.015873:0.010947:0.005627:0.011511:0.005508:0.011511:0.010263:0.011511:0.003250:0.008997:0.006465:0.003250:0.006465:0.006447:0.011032:0.005200:0.006447:0.010895:0.003250:0.003250:0.010263:0.003250:0.010895:0.011511:0.003250:0.006447:0.005627:0.004977:0.003250:0.011511:0.003250:0.006465:0.006445:0.011032:0.005200:0.006445:0.011340:0.010947:0.004079:0.004079:0.005627:0.003250:0.010263:0.003250:0.011494:0.004736:0.004738
erlotinib,  and  afatinib  in  advanced  EGFR-:@0.559966:0.864929:0.914519:0.864929:0.914519:0.850923:0.559966:0.850923:0.010947:0.004977:0.003250:0.011032:0.005627:0.003250:0.010263:0.003250:0.011494:0.004567:0.004738:0.003599:0.011511:0.010263:0.011545:0.004738:0.003597:0.011511:0.005200:0.011511:0.005627:0.003250:0.010263:0.003250:0.011494:0.004738:0.003599:0.003250:0.010263:0.004738:0.003599:0.011511:0.011545:0.009305:0.011511:0.010263:0.010895:0.010947:0.011545:0.004738:0.003597:0.008997:0.014744:0.008125:0.010211:0.005679
mutated non-small cell lung cancer. :@0.559966:0.879087:0.855777:0.879087:0.855777:0.865081:0.559966:0.865081:0.015873:0.010228:0.005627:0.011511:0.005627:0.010947:0.011545:0.004020:0.010263:0.011032:0.010263:0.005508:0.006465:0.015873:0.011511:0.003250:0.003250:0.004020:0.010895:0.010947:0.003250:0.003250:0.004020:0.003250:0.010228:0.010263:0.011340:0.004020:0.010895:0.011511:0.010263:0.010895:0.010947:0.003720:0.004567:0.004738
Journal :@0.855059:0.879087:0.919306:0.879087:0.919306:0.865081:0.855059:0.865081:0.008073:0.011032:0.010228:0.004977:0.010263:0.011511:0.003424:0.004738
of Thoracic Oncology.:@0.559966:0.893245:0.741512:0.893245:0.741512:0.879240:0.559966:0.879240:0.011032:0.005200:0.004567:0.007115:0.010263:0.011032:0.004977:0.011511:0.010895:0.003250:0.010895:0.004567:0.014693:0.010263:0.010895:0.011032:0.003250:0.011032:0.011340:0.008997:0.004738
 2017;12(4):633-43.:@0.741341:0.893245:0.889225:0.893245:0.889225:0.879240:0.741341:0.879240:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.006140:0.009305:0.006140:0.004567:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.004738
17.   Mok  TS, :@0.523619:0.907403:0.632991:0.907403:0.632991:0.893398:0.523619:0.893398:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.015719:0.011203:0.008586:0.004738:0.007499:0.007286:0.008518:0.004738:0.004738
et  al.:@0.640493:0.907403:0.689489:0.907403:0.689489:0.893398:0.640493:0.893398:0.011118:0.005798:0.004738:0.007500:0.011682:0.003421:0.004738
  Gefitinib  or  carboplatin- :@0.689489:0.907403:0.919265:0.907403:0.919265:0.893398:0.689489:0.893398:0.004738:0.007505:0.014915:0.011118:0.004165:0.004165:0.005798:0.003421:0.010434:0.003421:0.011665:0.004738:0.007504:0.011203:0.005148:0.004738:0.007497:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.005679:0.004738
paclitaxel in pulmonary adenocarcinoma. :@0.559966:0.921561:0.919277:0.921561:0.919277:0.907556:0.559966:0.907556:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.005850:0.003421:0.010434:0.005850:0.011665:0.010399:0.003421:0.016044:0.011203:0.010434:0.011682:0.005148:0.009168:0.005850:0.011682:0.011716:0.011118:0.010434:0.011203:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
N Engl J Med:@0.559966:0.935719:0.668168:0.935719:0.668168:0.921714:0.559966:0.921714:0.012657:0.004738:0.009168:0.010434:0.011511:0.003421:0.004738:0.008244:0.004738:0.015719:0.011118:0.011716
. 2009; 361:947-957.:@0.668151:0.935719:0.825443:0.935719:0.825443:0.921714:0.668151:0.921714:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738